Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines (R) Insights T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Horwitz, S. M., Ansell, S. M., Ai, W. Z., Barnes, J., Barta, S. K., Choi, M., Clemens, M. W., Dogan, A., Greer, J. P., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Kim, Y. H., Lunning, M. A., Mehta, A., Mehta-Shah, N., Oki, Y., Olsen, E. A., Pro, B., Rajguru, S. A., Shanbhag, S., Shustov, A., Sokol, L., Torka, P., Wilcox, R., William, B., Zain, J., Dwyer, M. A., Sundar, H. 2018; 16 (2): 123–35

Abstract

Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-cell lymphomas (ENKL) are rare malignancies, randomized trials comparing different regimens have not been conducted to date and standard therapy has not yet been established for these patients. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with ENKL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

View details for DOI 10.6004/jnccn.2018.0007

View details for Web of Science ID 000424512500005

View details for PubMedID 29439173